Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model. | Zendy

Joanna Jazowiecka-Rakus | Zendy; Stanisław Szala | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.

Author(s) -

Joanna Jazowiecka-Rakus,

Stanisław Szala

Publication year - 2004

Publication title -

acta biochimica polonica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.452

H-Index - 78

eISSN - 1734-154X

pISSN - 0001-527X

DOI - 10.18388/abp.2004_3569

Subject(s) - salmonella , cytosine deaminase , escherichia coli , microbiology and biotechnology , bacteria , enterobacteriaceae , melanoma , strain (injury) , ratón , biology , histology , gene , immunology , cancer research , genetic enhancement , biochemistry , genetics , anatomy

A tumour therapy is proposed based on attenuated Salmonella typhimurium VNP20047 expressing the Escherichia coli cytosine deaminase gene. VNP20047 was administered intravenously to B16(F10) melanoma-bearing C57BL/6 mice. VNP20047 proliferated within tumours and livers regardless of the initial inoculum dose. After 10 days the number of bacteria increased in livers up to 4.2 x 10(6) cfu/g and decreased in tumours down to 5.9 x 10(6) cfu/g. VNP20047 at 1 x 10(5) cfu/mouse, when combined with 5-fluorocytosine, inhibited tumour growth by 85% without prolonging animal survival. Histology studies revealed severe lesions in tumours and livers. These data suggest that S. typhimurium VNP20047 induced inflammatory responses, even though the strain was attenuated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research